Dedicated view
After Conservative / Palliative Care
This view includes only public records whose official title or study scope explicitly states advanced, metastatic, recurrent, refractory, later-line, supportive care, or palliative. TrialBeacon makes no screening judgment, matching, or recommendation — it simply gathers the literally relevant official entries together and provides direct links to the originals. Whether a record is still open, or relevant to any individual situation, should be determined from the official original and your physician’s judgment.
Showing the verified snapshot of official records indexed on 2026-08-16. Every link opens the live original page.
Includes only public records whose official title explicitly mentions advanced / recurrent / later-line / supportive care. No recommendations, no matching — only links to the originals. Defer to the official page and your physician’s judgment.
Please read this first. A record appearing here does not mean it is open, available or appropriate for any individual. Inclusion is based only on wording in the official record — never on any judgement by this site. Discuss anything you find with your treating doctor.
Trial records retrieved live from the ClinicalTrials.gov public API.
Select the public official records you want to take to your appointment, then generate a list. Nothing is ranked or recommended — the list only reproduces titles and links.
Not signed in — up to 5 records per list. Sign in for higher free limits, or see Pro for more exports.
A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors.
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients
Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression
Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
Assessing the Time Demands of Cancer
NK521 in the Treatment of Advanced Solid Tumors
Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer
A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer
Frailty, Quality Of Life and Early Reversal of Temporary Defunctioning Stoma in Ovarian Cancer
Study of AVZO-021 in Patients With Advanced Solid Tumors
The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors
Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
A Study of PHST001 in Advanced Solid Tumors
SMP-3124LP in Adults With Advanced Solid Tumors
ChiCTR — Chinese Clinical Trial Registry, public search
CTIS public register — search clinical trials authorised in the EU/EEA
ESMO Clinical Practice Guidelines — supportive and palliative care section
FDA — expanded access (compassionate use) information for patients
NCCN Guidelines — palliative care category listing
NCCN Guidelines for Patients — plain-language versions
药物临床试验登记与信息公示平台 — national registry of drug trials conducted in China
Whether a record is still open, current, or appropriate for any individual can only be confirmed by the official source and your treating doctor.
Ways to open the conversation with your doctor (reference only, not advice)
A template only — it teaches how to ask, and gives no answers. Adapt these to your own situation.
- Are these public records still searchable or open to enrolment?
- From the literal wording of the public titles, is there any point relevant to the current situation?
- If there is something relevant, what should I ask you about next?
- For symptoms, pain or supportive care, is there a public guideline worth prioritising as a reference?
These are only examples to help you start a conversation. They are not medical advice. All decisions should be made together with your treating doctor.